Steris (STE) Surpasses Q2 Earnings and Revenue Estimates

Core Insights - Steris (STE) reported quarterly earnings of $2.47 per share, exceeding the Zacks Consensus Estimate of $2.38 per share, and up from $2.14 per share a year ago, representing an earnings surprise of +3.78% [1] - The company achieved revenues of $1.46 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.31% and increasing from $1.33 billion year-over-year [2] - Steris shares have increased approximately 17.7% year-to-date, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.54, with expected revenues of $1.49 billion, and for the current fiscal year, the EPS estimate is $10.07 on revenues of $5.91 billion [7] - The trend of estimate revisions for Steris was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Sight Sciences, Inc. (SGHT), another company in the same industry, is expected to report a quarterly loss of $0.26 per share, reflecting a year-over-year decline of -18.2%, with revenues anticipated to be $17.16 million, down 14.9% from the previous year [9][10]